Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 47Neoplasms 5Neoplasm Metastasis 5Metastatic Castration-Resistant Prostate Cancer 3Adenocarcinoma 3Recurrence 2Prostatic Neoplasms, Castration-Resistant 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Bulbo-Spinal Atrophy, X-Linked 2mCRPC 1Triple Negative Breast Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sleep Initiation and Maintenance Disorders 1Prostate Cancer Metastatic 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasm, Residual 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Lymphoma, Follicular 1Fatigue 1Depression 1Colorectal Neoplasms 1Castration Resistant Metastatic Prostate Cancer 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1

Interventions

enzalutamide 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Hormone Sensitive Prostate Cancer × enzalutamide × 90 days × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡